Influenza remains a persistent global threat, with the rapid mutation of its surface proteins, particularly hemagglutinin (HA), challenging the effectiveness of seasonal vaccines. Universal vaccination seems to be a promising way of combatting the influenza virus's rapid mutation rate. The concept of a universal vaccine aims to provide broad protection against diverse strains by targeting conserved viral epitopes. In this review, I explored some of the major hurdles in achieving this goal, focusing on antigen selection, immunodominance, and the challenges posed by nanoparticle-based and T-cell-mediated vaccine platforms. The pursuit of a universal influenza vaccine faces numerous challenges despite advancements in the identification of conserved antigens and innovative technologies. Different types of vaccines have been put into clinical trials, such as viral vector and mRNA-based vaccines, non-replicating viral vector vaccines, and broadly neutralized antibodies (bnAbs), which have been proven to meet the research demands of the universal influenza vaccine. While promising, these approaches face significant barriers, including issues of antigen stability, delivery, and struggles of eliciting durable cross-reactive immune responses in mucosal tissues. Novel platforms like mRNA vaccines and viral vector vaccines show promise in providing broad protection against virus mutations. Breakthroughs in vaccine design continue to be made, aiming to enhance cross-protective efficacy and defense against potential pandemics. The results highlight that although significant progress has been made, overcoming the scientific, technical, and regulatory challenges is essential for achieving a truly universal influenza vaccine. In conclusion, ongoing global collaboration and innovative research are crucial for overcoming these barriers. However, the mutation rate of the influenza virus presents a significant obstacle in the path towards a commercially available universal vaccine.